[{"filename": "look-back-at-pharma-news-in-the-week-to-may-28-2021.json", "title": "Look back at pharma news in the week to May 28, 2021", "description": "Look back at pharma news in the week to May 28, 2021", "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-may-28-2021", "pubDate": "2021-05-30 11:41:00"}, {"filename": "amgen-scores-a-first-with-fda-approval-of-lumakras.json", "title": "Amgen scores a first with FDA approval of Lumakras", "description": "Amgen scores a first with FDA approval of Lumakras", "link": "https://www.thepharmaletter.com/article/amgen-scores-a-first-with-fda-approval-of-lumakras", "pubDate": "2021-05-29 15:43:00"}, {"filename": "fda-accelerated-appro-for-infigratinib-in-metastatic-cholangiocarcinoma.json", "title": "FDA accelerated appro for infigratinib in metastatic cholangiocarcinoma", "description": "FDA accelerated appro for infigratinib in metastatic cholangiocarcinoma", "link": "https://www.thepharmaletter.com/article/fda-accelerated-appro-for-infigratinib-in-metastatic-cholangiocarcinoma", "pubDate": "2021-05-29 15:31:00"}, {"filename": "lilly-gets-doj-subpoena-over-branchburg-manufacturing-site.json", "title": "Lilly gets DoJ subpoena over Branchburg manufacturing site", "description": "Eli Lilly has received a subpoena from the US Department of Justice (DoJ) requesting the production of certain documents relating to its manufacturing site in B", "link": "https://www.thepharmaletter.com/article/lilly-gets-doj-subpoena-over-branchburg-manufacturing-site", "pubDate": "2021-05-28 15:31:00"}, {"filename": "fourth-covid-19-vaccine-jab-gets-conditional-ok-in-uk.json", "title": "Fourth COVID-19 vaccine jab gets conditional OK in UK", "description": "Fourth COVID-19 vaccine jab gets conditional OK in UK", "link": "https://www.thepharmaletter.com/article/fourth-covid-19-vaccine-jab-gets-conditional-ok-in-uk", "pubDate": "2021-05-28 14:01:00"}, {"filename": "what-to-look-out-for-at-asco-2021.json", "title": "Our research highlights from ASCO 2021", "description": "The annual meeting of the American Society of Clinical Oncology (ASCO) kicks off online on 4 June, with more than 2,500 abstract presentations representing cutt", "link": "https://www.thepharmaletter.com/article/what-to-look-out-for-at-asco-2021", "pubDate": "2021-05-28 13:48:00"}, {"filename": "uk-reimbursement-win-for-tremfya-in-psoriatic-arthritis.json", "title": "UK reimbursement win for Tremfya in psoriatic arthritis", "description": "A positive reimbursement decision in the UK will enable Tremfya (guselkumab) to be offered for active psoriatic arthritis (PsA) through the country\u00e2\u0080\u0099s National H", "link": "https://www.thepharmaletter.com/article/uk-reimbursement-win-for-tremfya-in-psoriatic-arthritis", "pubDate": "2021-05-28 12:47:00"}, {"filename": "shield-therapeutics-appoints-new-ceo.json", "title": "Shield Therapeutics appoints new CEO", "description": "Shield Therapeutics appoints new CEO", "link": "https://www.thepharmaletter.com/article/shield-therapeutics-appoints-new-ceo", "pubDate": "2021-05-28 12:14:00"}, {"filename": "boehringer-s-bi-425809-has-potential-in-schizophrenia-market-says-analyst.json", "title": "Boehringer\u00e2\u0080\u0099s BI 425809 has potential in schizophrenia market, says analyst", "description": "Boehringer\u00e2\u0080\u0099s BI 425809 has potential in schizophrenia market, says analyst", "link": "https://www.thepharmaletter.com/article/boehringer-s-bi-425809-has-potential-in-schizophrenia-market-says-analyst", "pubDate": "2021-05-28 11:44:00"}, {"filename": "fda-nod-for-biohaven-s-nurtec-odt-for-migraine-prevention.json", "title": "FDA nod for Biohaven's Nurtec ODT for migraine prevention", "description": "FDA nod for Biohaven's Nurtec ODT for migraine prevention", "link": "https://www.thepharmaletter.com/article/fda-nod-for-biohaven-s-nurtec-odt-for-migraine-prevention", "pubDate": "2021-05-28 10:53:00"}, {"filename": "fda-approves-bristol-myers-zeposia-for-uc.json", "title": "FDA approves Bristol Myers\u00e2\u0080\u0099 Zeposia for UC", "description": "FDA approves Bristol Myers\u00e2\u0080\u0099 Zeposia for UC", "link": "https://www.thepharmaletter.com/article/fda-approves-bristol-myers-zeposia-for-uc", "pubDate": "2021-05-28 10:08:00"}, {"filename": "tagrisso-goes-full-steam-ahead-with-new-eu-approval.json", "title": "Tagrisso goes full steam ahead with new EU approval", "description": "Targeted therapies have been a game changer in EGFR-mutated lung cancer, with options such as Tagrisso (osimertinib), from AstraZeneca, helping to greatly impro", "link": "https://www.thepharmaletter.com/article/tagrisso-goes-full-steam-ahead-with-new-eu-approval", "pubDate": "2021-05-28 10:06:00"}, {"filename": "rdif-and-unicef-sign-sputnik-v-vaccine-supply-deal.json", "title": "RDIF and UNICEF sign Sputnik V vaccine supply\u00e2\u0080\u00afdeal", "description": "RDIF and UNICEF sign Sputnik V vaccine supply\u00e2\u0080\u00afdeal", "link": "https://www.thepharmaletter.com/article/rdif-and-unicef-sign-sputnik-v-vaccine-supply-deal", "pubDate": "2021-05-27 16:13:00"}, {"filename": "r-d-return-on-pharma-investment-picks-up-for-the-first-time-in-six-years-despite-pandemic.json", "title": "R&D return on pharma investment picks up for the first time in six years, despite pandemic", "description": "R&D return on pharma investment picks up for the first time in six years, despite pandemic", "link": "https://www.thepharmaletter.com/article/r-d-return-on-pharma-investment-picks-up-for-the-first-time-in-six-years-despite-pandemic", "pubDate": "2021-05-27 15:11:00"}, {"filename": "uae-seeks-investment-and-cooperation-with-indian-pharma.json", "title": "UAE seeks investment and cooperation with Indian pharma", "description": "UAE seeks investment and cooperation with Indian pharma", "link": "https://www.thepharmaletter.com/article/uae-seeks-investment-and-cooperation-with-indian-pharma", "pubDate": "2021-05-27 14:35:00"}, {"filename": "myfembree-approved-for-heavy-menstrual-bleeding-associated-with-uterine-fibroids.json", "title": "Myfembree approved for heavy menstrual bleeding associated with uterine fibroids", "description": NaN, "link": "https://www.thepharmaletter.com/article/myfembree-approved-for-heavy-menstrual-bleeding-associated-with-uterine-fibroids", "pubDate": "2021-05-27 14:06:00"}, {"filename": "probiogen-and-minapharm-incorporate-migentra.json", "title": "ProBioGen and Minapharm incorporate MiGenTra", "description": "ProBioGen and Minapharm incorporate MiGenTra", "link": "https://www.thepharmaletter.com/article/probiogen-and-minapharm-incorporate-migentra", "pubDate": "2021-05-27 13:44:00"}, {"filename": "global-nanomedicine-market-to-be-worth-258-billion-by-2025-says-report.json", "title": "Global nanomedicine market to be worth $258 billion by 2025, says report", "description": "The worldwide nanomedicine market, which was worth $141.34 billion in 2020, will rise to $258.11bn by 2025.", "link": "https://www.thepharmaletter.com/article/global-nanomedicine-market-to-be-worth-258-billion-by-2025-says-report", "pubDate": "2021-05-27 13:15:00"}, {"filename": "valirx-pulls-out-of-kth222-evaluation-deal.json", "title": "ValiRx pulls out of KTH222 evaluation deal", "description": "ValiRx pulls out of KTH222 evaluation deal", "link": "https://www.thepharmaletter.com/article/valirx-pulls-out-of-kth222-evaluation-deal", "pubDate": "2021-05-27 11:59:00"}, {"filename": "fda-green-light-for-gsk-and-vir-s-sotrovimab-in-covid-19.json", "title": "FDA green light for GSK and Vir\u00e2\u0080\u0099s sotrovimab in COVID-19", "description": "FDA green light for GSK and Vir\u00e2\u0080\u0099s sotrovimab in COVID-19", "link": "https://www.thepharmaletter.com/article/fda-green-light-for-gsk-and-vir-s-sotrovimab-in-covid-19", "pubDate": "2021-05-27 11:03:00"}, {"filename": "in-multiple-myeloma-more-competition-is-on-the-way.json", "title": "In multiple myeloma, more competition is on the way", "description": "The US regulator will consider a submission for novel cancer therapy ciltacabtagene autoleucel (cilta-cel) under the agency\u00e2\u0080\u0099s Priority Review scheme, with a dec", "link": "https://www.thepharmaletter.com/article/in-multiple-myeloma-more-competition-is-on-the-way", "pubDate": "2021-05-27 10:23:00"}, {"filename": "fda-curbs-use-of-liver-drug-ocaliva-on-safety-concerns.json", "title": "FDA curbs use of liver drug Ocaliva on safety concerns", "description": "FDA curbs use of liver drug Ocaliva on safety concerns", "link": "https://www.thepharmaletter.com/article/fda-curbs-use-of-liver-drug-ocaliva-on-safety-concerns", "pubDate": "2021-05-27 10:21:00"}, {"filename": "neuropathic-pain-market-forecast-to-reach-25-2-billion-by-2027.json", "title": "Neuropathic pain market forecast to reach $25.2 billion by 2027", "description": "Neuropathic pain market forecast to reach $25.2 billion by 2027", "link": "https://www.thepharmaletter.com/article/neuropathic-pain-market-forecast-to-reach-25-2-billion-by-2027", "pubDate": "2021-05-27 10:20:00"}, {"filename": "full-results-presented-on-pharmamar-s-aplidin-in-covid-19-requiring-hospitalization.json", "title": "Full results presented on PharmaMar\u00e2\u0080\u0099s Aplidin in COVID-19 requiring hospitalization", "description": "Spanish biopharma PharmaMar has announced the final results of its APLICOV-PC trial with Aplidin\u00c2\u00a0(plitidepsin) for the treatment of adults with COVID-19 requiri", "link": "https://www.thepharmaletter.com/article/full-results-presented-on-pharmamar-s-aplidin-in-covid-19-requiring-hospitalization", "pubDate": "2021-05-26 17:43:00"}, {"filename": "akili-bags-160-million-in-financing-poised-to-deliver-on-digital-therapeutics.json", "title": "Akili bags $160 million in financing; poised to deliver on digital therapeutics", "description": "Akili bags $160 million in financing; poised to deliver on digital therapeutics", "link": "https://www.thepharmaletter.com/article/akili-bags-160-million-in-financing-poised-to-deliver-on-digital-therapeutics", "pubDate": "2021-05-26 16:18:00"}, {"filename": "bluerock-and-senti-bio-to-work-together-on-advanced-therapies.json", "title": "BlueRock and Senti Bio to work together on advanced therapies", "description": "Cell therapy specialist and Bayer subsidiary BlueRock Therapeutics is to work together with fellow USA-based company Senti Biosciences (Senti Bio) on the latter", "link": "https://www.thepharmaletter.com/article/bluerock-and-senti-bio-to-work-together-on-advanced-therapies", "pubDate": "2021-05-26 15:47:00"}, {"filename": "abivax-reports-excellent-efficacy-and-safety-of-abx464-in-phase-iib.json", "title": "Abivax reports excellent efficacy and safety of ABX464 in Phase IIb", "description": "Abivax reports excellent efficacy and safety of ABX464 in Phase IIb", "link": "https://www.thepharmaletter.com/article/abivax-reports-excellent-efficacy-and-safety-of-abx464-in-phase-iib", "pubDate": "2021-05-26 15:28:00"}, {"filename": "uk-competition-watchdog-weighs-in-on-alexion-purchase.json", "title": "UK competition watchdog weighs in on Alexion purchase", "description": NaN, "link": "https://www.thepharmaletter.com/article/uk-competition-watchdog-weighs-in-on-alexion-purchase", "pubDate": "2021-05-26 15:22:00"}, {"filename": "mood-music-improves-for-type-1-diabetes-candidate.json", "title": "Mood music improves for type 1 diabetes candidate", "description": "Shares in New Jersey, USA-based company Provention Bio rose by over a quarter on Tuesday, after the firm announced positive regulatory news related to its type ", "link": "https://www.thepharmaletter.com/article/mood-music-improves-for-type-1-diabetes-candidate", "pubDate": "2021-05-26 14:59:00"}, {"filename": "ysios-capital-closes-its-third-fund-at-260-million.json", "title": "Ysios Capital closes its third fund at $260 million", "description": "Ysios Capital closes its third fund at $260 million", "link": "https://www.thepharmaletter.com/article/ysios-capital-closes-its-third-fund-at-260-million", "pubDate": "2021-05-26 14:50:00"}, {"filename": "call-for-advanced-therapies-to-be-exempt-from-eu-gmo-legislation.json", "title": "Call for advanced therapies to be exempt from EU GMO legislation", "description": "The European Commission (EC) should exempt advanced therapies from Genetically Modified Organism (GMO) legislation, which hurts Europe\u00e2\u0080\u0099s ability to attract clin", "link": "https://www.thepharmaletter.com/article/call-for-advanced-therapies-to-be-exempt-from-eu-gmo-legislation", "pubDate": "2021-05-26 13:11:00"}, {"filename": "icer-protocol-for-assessing-drug-coverage-policies-and-barriers-to-fair-access.json", "title": "ICER protocol for assessing drug coverage policies and barriers to fair access", "description": "ICER protocol for assessing drug coverage policies and barriers to fair access", "link": "https://www.thepharmaletter.com/article/icer-protocol-for-assessing-drug-coverage-policies-and-barriers-to-fair-access", "pubDate": "2021-05-26 12:26:00"}, {"filename": "ip-waiver-talks-hinge-on-use-of-big-pharma-s-trade-secrets.json", "title": "IP waiver talks hinge on use of Big Pharma's trade secrets", "description": "IP waiver talks hinge on use of Big Pharma's trade secrets", "link": "https://www.thepharmaletter.com/article/ip-waiver-talks-hinge-on-use-of-big-pharma-s-trade-secrets", "pubDate": "2021-05-26 11:39:00"}, {"filename": "fda-accepts-bla-for-ublituximab-ukoniq-in-leukemia-and-lymphoma-indications.json", "title": "FDA accepts BLA for ublituximab + Ukoniq in leukemia and lymphoma indications", "description": "FDA accepts BLA for Ublituximab + Ukoniq in leukemia and lymphoma indications", "link": "https://www.thepharmaletter.com/article/fda-accepts-bla-for-ublituximab-ukoniq-in-leukemia-and-lymphoma-indications", "pubDate": "2021-05-26 11:06:00"}, {"filename": "ec-approves-venclyxto-based-combo-for-acute-myeloid-leukemia.json", "title": "EC approves Venclyxto-based combo for acute myeloid leukemia", "description": "EC approves Venclyxto-based combo for acute myeloid leukemia", "link": "https://www.thepharmaletter.com/article/ec-approves-venclyxto-based-combo-for-acute-myeloid-leukemia", "pubDate": "2021-05-26 10:19:00"}, {"filename": "pieris-to-pocket-potential-1-4-billion-from-roche-deal.json", "title": "Pieris to pocket potential $1.4 billion from Roche deal", "description": "Shares in US biotech Pieris Pharmaceuticals rocketed by nearly 50% in three hours of trading on Tuesday on news of a multi-program research collaboration and li", "link": "https://www.thepharmaletter.com/article/pieris-to-pocket-potential-1-4-billion-from-roche-deal", "pubDate": "2021-05-25 17:46:00"}, {"filename": "keytruda-lynparza-and-lenvima-central-to-merck-co-s-asco-offering.json", "title": "Keytruda, Lynparza and Lenvima central to Merck & Co\u00e2\u0080\u0099s ASCO offering", "description": "US pharma major Merck & Co\u00e2\u0080\u0099s presentations at this year\u00e2\u0080\u0099s ASCO annual meeting will focus primarily on three products.", "link": "https://www.thepharmaletter.com/article/keytruda-lynparza-and-lenvima-central-to-merck-co-s-asco-offering", "pubDate": "2021-05-25 16:50:00"}, {"filename": "positive-top-line-results-from-phase-iii-prince-study-of-pegcetacoplan-in-pnh.json", "title": "Positive top-line results from Phase III PRINCE study of pegcetacoplan in PNH", "description": "Positive top-line results from Phase III PRINCE study of pegcetacoplan in PNH", "link": "https://www.thepharmaletter.com/article/positive-top-line-results-from-phase-iii-prince-study-of-pegcetacoplan-in-pnh", "pubDate": "2021-05-25 16:42:00"}, {"filename": "positive-data-for-moderna-vaccine-in-adolescents.json", "title": "Positive data for Moderna vaccine in adolescents", "description": "American messenger RNA specialist Moderna has announced positive results from a study of its COVID-19 vaccine (mRNA-1273) in adolescents.", "link": "https://www.thepharmaletter.com/article/positive-data-for-moderna-vaccine-in-adolescents", "pubDate": "2021-05-25 16:08:00"}, {"filename": "zelluna-inks-deals-to-develop-and-commercialize-mage-a4-and-vgll1.json", "title": "Zelluna inks deals on MAGE-A4 and VGLL1 targeting for solid tumors", "description": "Zelluna inks deals on MAGE-A4 and VGLL1 targeting for solid tumors", "link": "https://www.thepharmaletter.com/article/zelluna-inks-deals-to-develop-and-commercialize-mage-a4-and-vgll1", "pubDate": "2021-05-25 15:53:00"}, {"filename": "european-commission-approves-ponvory-for-rms.json", "title": "European Commission approves Ponvory for RMS", "description": "European Commission approves Ponvory for RMS", "link": "https://www.thepharmaletter.com/article/european-commission-approves-ponvory-for-rms", "pubDate": "2021-05-25 15:24:00"}, {"filename": "tillotts-pharma-continues-growth-with-launch-in-benelux.json", "title": "Tillotts Pharma continues growth with launch in Benelux", "description": "Tillotts Pharma continues growth with launch in Benelux", "link": "https://www.thepharmaletter.com/article/tillotts-pharma-continues-growth-with-launch-in-benelux", "pubDate": "2021-05-25 13:29:00"}, {"filename": "verastem-combination-wins-breakthrough-status.json", "title": "Verastem combination wins breakthrough status", "description": "The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Verastem\u00e2\u0080\u0099s investigational RAF/MEK inhibitor VS-6766.combined with de", "link": "https://www.thepharmaletter.com/article/verastem-combination-wins-breakthrough-status", "pubDate": "2021-05-25 13:21:00"}, {"filename": "viral-vector-crunch-as-gene-therapies-vaccines-take-off.json", "title": "Viral vector crunch as gene therapies, vaccines take off", "description": "A new report from industry analyst GlobalData finds that the global biotech industry is experiencing a shortage of viral vectors, an essential component of adva", "link": "https://www.thepharmaletter.com/article/viral-vector-crunch-as-gene-therapies-vaccines-take-off", "pubDate": "2021-05-25 13:12:00"}, {"filename": "us-legislation-proposes-funding-trials-amid-covid-19-delays.json", "title": "US legislation proposes funding trials amid COVID-19 delays", "description": "New bipartisan legislation has been proposed by two US Representatives that would fund critical research on treatments and cures for diseases including Alzheime", "link": "https://www.thepharmaletter.com/article/us-legislation-proposes-funding-trials-amid-covid-19-delays", "pubDate": "2021-05-25 12:14:00"}, {"filename": "ngm-bio-adds-to-woes-in-the-search-for-a-nash-treatment.json", "title": "NGM Bio adds to woes in the search for a NASH treatment", "description": "NGM Bio adds to woes in the search for a NASH treatment", "link": "https://www.thepharmaletter.com/article/ngm-bio-adds-to-woes-in-the-search-for-a-nash-treatment", "pubDate": "2021-05-25 11:57:00"}, {"filename": "keytruda-challenger-takes-center-stage-at-asco-2021.json", "title": "Keytruda challenger takes center stage at ASCO 2021", "description": "This year\u00e2\u0080\u0099s annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for Shanghai\u00e2\u0080\u0099s Junshi Biosciences (HKEX: 1877) to shine.", "link": "https://www.thepharmaletter.com/article/keytruda-challenger-takes-center-stage-at-asco-2021", "pubDate": "2021-05-25 11:04:00"}, {"filename": "russia-s-natsimbio-to-develop-new-complex-covid-19-vaccine.json", "title": "Russia\u00e2\u0080\u0099s Natsimbio to develop new complex COVID-19 vaccine", "description": "Russia\u00e2\u0080\u0099s Natsimbio to develop new complex COVID-19 vaccine", "link": "https://www.thepharmaletter.com/article/russia-s-natsimbio-to-develop-new-complex-covid-19-vaccine", "pubDate": "2021-05-25 10:48:00"}, {"filename": "russian-government-to-use-interventions-in-domestic-pharma-pricing.json", "title": "Russian government to use interventions in domestic pharma pricing", "description": "Russian government to use interventions in domestic pharma pricing", "link": "https://www.thepharmaletter.com/article/russian-government-to-use-interventions-in-domestic-pharma-pricing", "pubDate": "2021-05-25 10:21:00"}, {"filename": "full-program-for-astrazeneca-at-asco-2021.json", "title": "Full program for AstraZeneca at ASCO 2021", "description": "While UK-based drugmaker AstraZeneca has mostly made headlines for its development of a coronavirus vaccine, the firm\u00e2\u0080\u0099s work in oncology is potentially of great", "link": "https://www.thepharmaletter.com/article/full-program-for-astrazeneca-at-asco-2021", "pubDate": "2021-05-25 10:19:00"}, {"filename": "asco-2021-novartis-readies-varied-portfolio.json", "title": "ASCO 2021: Novartis readies varied portfolio", "description": "Swiss pharma giant Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at", "link": "https://www.thepharmaletter.com/article/asco-2021-novartis-readies-varied-portfolio", "pubDate": "2021-05-25 10:18:00"}, {"filename": "breakthrough-designation-for-boehringer-s-drug-for-cognitive-impairment-associated-with-schizophrenia.json", "title": "Breakthrough designation for Boehringer\u00e2\u0080\u0099s drug for cognitive impairment associated with schizophrenia", "description": "The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Boehringer Ingelheim\u00e2\u0080\u0099s BI 425809 for the treatment of cognitive", "link": "https://www.thepharmaletter.com/article/breakthrough-designation-for-boehringer-s-drug-for-cognitive-impairment-associated-with-schizophrenia", "pubDate": "2021-05-24 17:59:00"}, {"filename": "further-impressive-data-for-takeda-s-dengue-vaccine.json", "title": "Further impressive data for Takeda's dengue vaccine", "description": "Takeda\u00e2\u0080\u0099s dengue vaccine candidate (TAK-003) has demonstrated continued protection against illness and hospitalization.regardless of a person\u00e2\u0080\u0099s previous dengue e", "link": "https://www.thepharmaletter.com/article/further-impressive-data-for-takeda-s-dengue-vaccine", "pubDate": "2021-05-24 17:12:00"}, {"filename": "xeris-to-acquire-strongbridge-biopharma-in-stock-and-cvr-transaction.json", "title": "Xeris to acquire Strongbridge Biopharma in stock and CVR transaction", "description": "Xeris to acquire Strongbridge Biopharma in stock and CVR transaction", "link": "https://www.thepharmaletter.com/article/xeris-to-acquire-strongbridge-biopharma-in-stock-and-cvr-transaction", "pubDate": "2021-05-24 16:47:00"}, {"filename": "rdif-and-panacea-biotec-launch-the-production-of-sputnik-v-in-india.json", "title": "RDIF and Panacea Biotec launch the production of Sputnik V in India", "description": "RDIF and Panacea Biotec launch the production of Sputnik V in India", "link": "https://www.thepharmaletter.com/article/rdif-and-panacea-biotec-launch-the-production-of-sputnik-v-in-india", "pubDate": "2021-05-24 14:09:00"}, {"filename": "roche-s-covid-19-antibody-cocktail-now-available-in-india-marketed-by-cipla.json", "title": "Roche\u00e2\u0080\u0099s COVID-19 antibody cocktail now available in India, marketed by Cipla", "description": "Roche\u00e2\u0080\u0099s COVID-19 antibody cocktail now available in India, marketed by Cipla", "link": "https://www.thepharmaletter.com/article/roche-s-covid-19-antibody-cocktail-now-available-in-india-marketed-by-cipla", "pubDate": "2021-05-24 12:29:00"}, {"filename": "signs-of-a-possible-breakthrough-in-alzheimer-s-and-parkinson-s.json", "title": "Signs of a possible breakthrough in Alzheimer's and Parkinson's", "description": NaN, "link": "https://www.thepharmaletter.com/article/signs-of-a-possible-breakthrough-in-alzheimer-s-and-parkinson-s", "pubDate": "2021-05-24 12:18:00"}, {"filename": "uk-study-shows-robust-vaccine-effectiveness-against-indian-strain.json", "title": "UK study shows robust vaccine effectiveness against Indian strain", "description": "Real-world evidence from public health authorities in the UK suggest that coronavirus vaccines from Pfizer and BioNTech, and AstraZeneca, are effective against ", "link": "https://www.thepharmaletter.com/article/uk-study-shows-robust-vaccine-effectiveness-against-indian-strain", "pubDate": "2021-05-24 11:07:00"}, {"filename": "the-fda-s-commitment-to-secure-drug-distribution.json", "title": "The FDA\u00e2\u0080\u0099s commitment to secure drug distribution", "description": "The FDA\u00e2\u0080\u0099s commitment to secure drug distribution", "link": "https://www.thepharmaletter.com/article/the-fda-s-commitment-to-secure-drug-distribution", "pubDate": "2021-05-24 11:00:00"}, {"filename": "pharmacological-treatments-for-ehlers-danlos-syndrome-eds.json", "title": "Pharmacological treatments for Ehlers-Danlos syndrome (EDS)", "description": "Pharmacological treatments for Ehlers-Danlos syndrome (EDS)", "link": "https://www.thepharmaletter.com/article/pharmacological-treatments-for-ehlers-danlos-syndrome-eds", "pubDate": "2021-05-24 10:36:00"}, {"filename": "south-korean-approval-and-production-deal-for-moderna-s-covid-19-vaccine.json", "title": "South Korean approval and production deal for Moderna\u00e2\u0080\u0099s COVID-19 vaccine", "description": "South Korean approval and production deal for Moderna\u00e2\u0080\u0099s COVID-19 vaccine", "link": "https://www.thepharmaletter.com/article/south-korean-approval-and-production-deal-for-moderna-s-covid-19-vaccine", "pubDate": "2021-05-24 10:21:00"}, {"filename": "positive-data-4d-pharma-s-blautix-in-irritable-bowel-syndrome.json", "title": "Positive data 4D pharma\u00e2\u0080\u0099s Blautix in irritable bowel syndrome", "description": "Positive data 4D pharma\u00e2\u0080\u0099s Blautix in irritable bowel syndrome", "link": "https://www.thepharmaletter.com/article/positive-data-4d-pharma-s-blautix-in-irritable-bowel-syndrome", "pubDate": "2021-05-24 10:20:00"}, {"filename": "look-back-at-pharma-news-in-the-week-to-may-21-2021.json", "title": "Look back at pharma news in the week to May 21, 2021", "description": "Look back at pharma news in the week to May 21, 2021", "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-may-21-2021", "pubDate": "2021-05-23 10:49:00"}, {"filename": "fda-green-light-for-first-targeted-therapy-for-subset-of-nsclc.json", "title": "FDA green light for first targeted therapy for subset of NSCLC", "description": "FDA green light for first targeted therapy for subset of NSCLC", "link": "https://www.thepharmaletter.com/article/fda-green-light-for-first-targeted-therapy-for-subset-of-nsclc", "pubDate": "2021-05-22 15:27:00"}, {"filename": "beigene-releases-positive-top-line-phase-iii-results-on-tislelizumab-in-npc.json", "title": "BeiGene releases positive top-line Phase III results on tislelizumab in NPC", "description": "BeiGene releases positive top-line Phase III results on tislelizumab in NPC", "link": "https://www.thepharmaletter.com/article/beigene-releases-positive-top-line-phase-iii-results-on-tislelizumab-in-npc", "pubDate": "2021-05-22 14:32:00"}, {"filename": "plaque-psoriasis-prospect-roflumilast-predicted-to-launch-in-2022.json", "title": "Plaque psoriasis prospect roflumilast predicted to launch in 2022", "description": "GlobalData has taken a look at the data supporting roflumilast for plaque psoriasis (PsO).", "link": "https://www.thepharmaletter.com/article/plaque-psoriasis-prospect-roflumilast-predicted-to-launch-in-2022", "pubDate": "2021-05-21 16:47:00"}, {"filename": "positive-ema-scientific-opinion-for-sotrovimab-as-covid-19-therapy.json", "title": "Positive EMA scientific opinion for sotrovimab as COVID-19 therapy", "description": "Positive EMA scientific opinion for sotrovimab as COVID-19 therapy", "link": "https://www.thepharmaletter.com/article/positive-ema-scientific-opinion-for-sotrovimab-as-covid-19-therapy", "pubDate": "2021-05-21 16:22:00"}, {"filename": "batch-of-new-drug-ema-chmp-recommendations-for-may-2021.json", "title": "Batch of new drug EMA/CHMP recommendations for May 2021", "description": "Batch of new drug EMA/CHMP recommendations for May 2021", "link": "https://www.thepharmaletter.com/article/batch-of-new-drug-ema-chmp-recommendations-for-may-2021", "pubDate": "2021-05-21 15:49:00"}, {"filename": "lilly-closes-up-as-tirzepatide-compares-favorably-with-insulin-glargine.json", "title": "Lilly closes up as tirzepatide compares favorably with insulin glargine", "description": "Eli Lilly\u00e2\u0080\u0099s tirzepatide has achieved all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiova", "link": "https://www.thepharmaletter.com/article/lilly-closes-up-as-tirzepatide-compares-favorably-with-insulin-glargine", "pubDate": "2021-05-21 15:09:00"}, {"filename": "pfizer-biontech-covid-19-vaccine-shelf-life-extended-to-31-days.json", "title": "Pfizer/BioNTech COVID-19 vaccine shelf-life extended to 31 days", "description": "Pfizer/BioNTech COVID-19 vaccine shelf-life extended to 31 days", "link": "https://www.thepharmaletter.com/article/pfizer-biontech-covid-19-vaccine-shelf-life-extended-to-31-days", "pubDate": "2021-05-21 14:55:00"}, {"filename": "objective-responses-for-astellas-and-seagen-s-padcev-keytruda-combo-in-urothelial-cancer.json", "title": "Objective responses for Astellas and Seagen\u00e2\u0080\u0099s Padcev/Keytruda combo in urothelial cancer", "description": "Objective responses for Astellas and Seagen\u00e2\u0080\u0099s Padcev/Keytruda combo in urothelial cancer", "link": "https://www.thepharmaletter.com/article/objective-responses-for-astellas-and-seagen-s-padcev-keytruda-combo-in-urothelial-cancer", "pubDate": "2021-05-21 14:25:00"}, {"filename": "sosei-heptares-hits-milestone-in-pfizer-collaboration.json", "title": "Sosei Heptares hits milestone in Pfizer collaboration", "description": "Sosei Heptares hits milestone in Pfizer collaboration", "link": "https://www.thepharmaletter.com/article/sosei-heptares-hits-milestone-in-pfizer-collaboration", "pubDate": "2021-05-21 12:15:00"}, {"filename": "double-dose-of-vaccine-approvals-in-japan.json", "title": "Double dose of COVID-19 vaccine approvals in Japan", "description": "With the Olympic Games just a couple of months away and coronavirus cases in the country at a dangerous point, Japan has approved two vaccines in a single day.", "link": "https://www.thepharmaletter.com/article/double-dose-of-vaccine-approvals-in-japan", "pubDate": "2021-05-21 12:08:00"}, {"filename": "strategic-reorganization-increased-investment-reaffirm-daiichi-sankyo-s-long-term-oncology-goals.json", "title": "Strategic reorganization, increased investment reaffirm Daiichi Sankyo\u00e2\u0080\u0099s long-term oncology goals", "description": "Strategic reorganization, increased investment reaffirm Daiichi Sankyo\u00e2\u0080\u0099s long-term oncology goals", "link": "https://www.thepharmaletter.com/article/strategic-reorganization-increased-investment-reaffirm-daiichi-sankyo-s-long-term-oncology-goals", "pubDate": "2021-05-21 11:14:00"}, {"filename": "fda-approves-opdivo-for-resected-esophageal-or-gej-cancer.json", "title": "FDA approves Opdivo for resected esophageal or GEJ cancer", "description": "FDA approves Opdivo for resected esophageal or GEJ cancer", "link": "https://www.thepharmaletter.com/article/fda-approves-opdivo-for-resected-esophageal-or-gej-cancer", "pubDate": "2021-05-21 10:34:00"}, {"filename": "what-do-amazon-and-netflix-have-in-common-with-pharma-s-hcp-engagement-model-more-than-you-think.json", "title": "What do Amazon and Netflix have in common with pharma\u00e2\u0080\u0099s HCP engagement model? More than you think", "description": "AJ Ploszay, VP of digital strategy, IQVIA, provides an Expert View on how the precedent for consumer buying set by companies like Amazon, further accelerated by", "link": "https://www.thepharmaletter.com/article/what-do-amazon-and-netflix-have-in-common-with-pharma-s-hcp-engagement-model-more-than-you-think", "pubDate": "2021-05-20 18:00:00"}, {"filename": "ema-and-mhra-validate-regulatory-applications-for-new-use-of-kaftrio.json", "title": "EMA and MHRA validate regulatory applications for new use of Kaftrio", "description": "EMA and MHRA validate regulatory applications for new use of Kaftrio", "link": "https://www.thepharmaletter.com/article/ema-and-mhra-validate-regulatory-applications-for-new-use-of-kaftrio", "pubDate": "2021-05-20 15:39:00"}, {"filename": "r-pharm-reports-positive-new-data-on-ra-drug-olokizumab.json", "title": "R-Pharm reports positive new data on RA drug olokizumab", "description": "R-Pharm reports positive new data on RA drug olokizumab", "link": "https://www.thepharmaletter.com/article/r-pharm-reports-positive-new-data-on-ra-drug-olokizumab", "pubDate": "2021-05-20 14:53:00"}, {"filename": "ec-signs-up-for-1-8-billion-additional-doses-of-comirnaty.json", "title": "EC signs up for 1.8 billion additional doses of Comirnaty", "description": "EC signs up for 1.8 billion additional doses of Comirnaty", "link": "https://www.thepharmaletter.com/article/ec-signs-up-for-1-8-billion-additional-doses-of-comirnaty", "pubDate": "2021-05-20 12:35:00"}, {"filename": "survey-finds-positivity-about-uk-s-post-brexit-healthcare-research-landscape.json", "title": "Survey finds positivity about UK\u00e2\u0080\u0099s post-Brexit healthcare research landscape", "description": "American and British healthcare industry professionals are positive the UK will remain an attractive destination for healthcare research post-Brexit, according ", "link": "https://www.thepharmaletter.com/article/survey-finds-positivity-about-uk-s-post-brexit-healthcare-research-landscape", "pubDate": "2021-05-20 12:20:00"}, {"filename": "numab-completes-oversubscribed-110-million-financing.json", "title": "Numab completes oversubscribed $110 million financing", "description": "Numab completes oversubscribed $110 million financing", "link": "https://www.thepharmaletter.com/article/numab-completes-oversubscribed-110-million-financing", "pubDate": "2021-05-20 11:37:00"}, {"filename": "asco-2021-bristol-myers-boasts-next-gen-checkpoint-blocker.json", "title": "ASCO 2021: Bristol Myers boasts next-gen checkpoint blocker", "description": "At this year\u00e2\u0080\u0099s ASCO meeting, Bristol Myers Squibb will present the first data from a Phase III trial evaluating a LAG-3-blocking antibody.", "link": "https://www.thepharmaletter.com/article/asco-2021-bristol-myers-boasts-next-gen-checkpoint-blocker", "pubDate": "2021-05-20 10:56:00"}, {"filename": "hibercell-closes-67-4-million-series-b-financing.json", "title": "HiberCell closes $67.4 million Series B financing", "description": "HiberCell closes $67.4 million Series B financing", "link": "https://www.thepharmaletter.com/article/hibercell-closes-67-4-million-series-b-financing", "pubDate": "2021-05-20 10:53:00"}, {"filename": "positive-pivotal-phase-iii-data-for-roche-s-tecentriq.json", "title": "Positive pivotal Phase III data for Roche\u00e2\u0080\u0099s Tecentriq", "description": "Positive pivotal Phase III data for Roche\u00e2\u0080\u0099s Tecentriq", "link": "https://www.thepharmaletter.com/article/positive-pivotal-phase-iii-data-for-roche-s-tecentriq", "pubDate": "2021-05-20 10:32:00"}, {"filename": "fasenra-asthma-safety-and-efficacy-stretch-to-five-years.json", "title": "Fasenra asthma safety and efficacy stretch to five years", "description": "The AstraZeneca drug Fasenra (benralizumab) has been shown to be well-tolerated for up to five years, with a long-term safety profile consistent with previous P", "link": "https://www.thepharmaletter.com/article/fasenra-asthma-safety-and-efficacy-stretch-to-five-years", "pubDate": "2021-05-19 18:04:00"}, {"filename": "agenus-set-to-earn-up-to-1-56-billion-in-antibody-deal-with-bms.json", "title": "Agenus set to earn up to $1.56 billion in antibody deal with BMS", "description": "Agenus set to earn up to $1.56 billion in antibody deal with BMS", "link": "https://www.thepharmaletter.com/article/agenus-set-to-earn-up-to-1-56-billion-in-antibody-deal-with-bms", "pubDate": "2021-05-19 17:00:00"}, {"filename": "chugai-launches-polivy-intravenous-infusion-for-diffuse-large-b-cell-lymphoma.json", "title": "Chugai launches Polivy intravenous infusion for diffuse large B-cell lymphoma", "description": "The Roche (ROG: SIX) unit Chugai has announced the launch of Polivy (polatuzumab vedotin) intravenous infusion 30mg and 140mg for the treatment of relapsed or r", "link": "https://www.thepharmaletter.com/article/chugai-launches-polivy-intravenous-infusion-for-diffuse-large-b-cell-lymphoma", "pubDate": "2021-05-19 16:26:00"}, {"filename": "apeiron-s-apn01-selected-for-large-scale-us-trial-in-covid-19.json", "title": "APEIRON\u00e2\u0080\u0099s APN01 selected for large-scale US trial in COVID-19", "description": "APEIRON\u00e2\u0080\u0099s APN01 selected for large-scale US trial in COVID-19", "link": "https://www.thepharmaletter.com/article/apeiron-s-apn01-selected-for-large-scale-us-trial-in-covid-19", "pubDate": "2021-05-19 15:43:00"}, {"filename": "despite-pandemic-r-d-remains-robust-finds-industry-analyst.json", "title": "Despite pandemic R&D remains robust, finds industry analyst", "description": "Industry analyst IQVIA has conducted research into global R&D trends in the pharmaceutical industry, finding that notwithstanding significant disruption activit", "link": "https://www.thepharmaletter.com/article/despite-pandemic-r-d-remains-robust-finds-industry-analyst", "pubDate": "2021-05-19 13:00:00"}, {"filename": "global-life-sciences-industry-calls-for-action-on-vaccine-access.json", "title": "Global life sciences industry calls for action on vaccine access", "description": "Trade bodies representing the global life sciences industry have come together to urge coordinated steps to improve access to coronavirus vaccines.", "link": "https://www.thepharmaletter.com/article/global-life-sciences-industry-calls-for-action-on-vaccine-access", "pubDate": "2021-05-19 12:23:00"}, {"filename": "eisai-launches-remitoro-for-ptcl-and-ctcl-in-japan.json", "title": "Eisai launches Remitoro for PTCL and CTCL in Japan", "description": "Eisai launches Remitoro for PTCL and CTCL in Japan", "link": "https://www.thepharmaletter.com/article/eisai-launches-remitoro-for-ptcl-and-ctcl-in-japan", "pubDate": "2021-05-19 12:08:00"}, {"filename": "early-stage-trial-shows-positive-profile-for-sarepta-s-dmd-candidate-srp-9001.json", "title": "Early-stage trial shows positive profile for Sarepta\u00e2\u0080\u0099s DMD candidate SRP-9001", "description": "Early-stage trial shows positive profile for Sarepta\u00e2\u0080\u0099s DMD candidate SRP-9001", "link": "https://www.thepharmaletter.com/article/early-stage-trial-shows-positive-profile-for-sarepta-s-dmd-candidate-srp-9001", "pubDate": "2021-05-19 11:11:00"}, {"filename": "india-set-to-attract-fdi-and-exploit-covid-19-created-opportunities.json", "title": "India set to attract FDI and exploit COVID-19 created opportunities", "description": "India set to attract FDI and exploit COVID-19 created opportunities", "link": "https://www.thepharmaletter.com/article/india-set-to-attract-fdi-and-exploit-covid-19-created-opportunities", "pubDate": "2021-05-19 10:47:00"}, {"filename": "gamma-biosciences-takes-controlling-stake-in-mirus-bio.json", "title": "Gamma Biosciences takes controlling stake in Mirus Bio", "description": "Gamma Biosciences takes controlling stake in Mirus Bio", "link": "https://www.thepharmaletter.com/article/gamma-biosciences-takes-controlling-stake-in-mirus-bio", "pubDate": "2021-05-19 10:34:00"}, {"filename": "bluerock-in-ophthalmology-r-d-alliance.json", "title": "BlueRock in ophthalmology R&D alliance", "description": "The Bayer subsidiary BlueRock Therapeutics and FUJIFILM Cellular Dynamics (FCDI), a developer and manufacturer of human induced pluripotent stem (iPS) cell tech", "link": "https://www.thepharmaletter.com/article/bluerock-in-ophthalmology-r-d-alliance", "pubDate": "2021-05-18 21:23:00"}, {"filename": "new-lobby-group-for-advanced-therapies-launches-in-the-uk.json", "title": "New lobby group for advanced therapies launches in the UK", "description": "Advanced therapy manufacturers in the UK have come together to raise awareness of the potential of next generation therapies and to support their development.", "link": "https://www.thepharmaletter.com/article/new-lobby-group-for-advanced-therapies-launches-in-the-uk", "pubDate": "2021-05-18 17:48:00"}, {"filename": "european-pharma-industry-calls-for-strategic-reform-to-stay-competitive.json", "title": "European pharma industry calls for strategic reform to stay competitive", "description": "Medicines for Europe, the trade group representing the generics and biosimilars industry in Europe, has welcomed an update to the 2020 industrial strategy publi", "link": "https://www.thepharmaletter.com/article/european-pharma-industry-calls-for-strategic-reform-to-stay-competitive", "pubDate": "2021-05-18 16:43:00"}, {"filename": "executive-moves-at-merck-s-healthcare-business-sector.json", "title": "Executive moves at Merck\u00e2\u0080\u0099s Healthcare business sector", "description": "Executive moves at Merck\u00e2\u0080\u0099s Healthcare business sector", "link": "https://www.thepharmaletter.com/article/executive-moves-at-merck-s-healthcare-business-sector", "pubDate": "2021-05-18 16:30:00"}, {"filename": "mestag-teams-up-with-janssen-in-inflammatory-disease.json", "title": "Mestag teams up with Janssen in inflammatory disease", "description": "UK breakthrough inflammatory disease and immuno-oncology company Mestag Therapeutics has announced a target discovery, option and license agreement with Janssen", "link": "https://www.thepharmaletter.com/article/mestag-teams-up-with-janssen-in-inflammatory-disease", "pubDate": "2021-05-18 15:23:00"}, {"filename": "china-nmpa-accepts-bla-for-sacituzumab-govitecan-hziy-in-breast-cancer.json", "title": "China NMPA accepts BLA for sacituzumab govitecan-hziy in breast cancer", "description": "China NMPA accepts BLA for sacituzumab govitecan-hziy in breast cancer", "link": "https://www.thepharmaletter.com/article/china-nmpa-accepts-bla-for-sacituzumab-govitecan-hziy-in-breast-cancer", "pubDate": "2021-05-18 14:37:00"}, {"filename": "phase-ii-success-for-plant-based-vaccine-from-medicago-and-gsk.json", "title": "Phase II success for plant-based vaccine from Medicago and GSK", "description": "Medicago and UK-based drugmaker GlaxoSmithKline have reported positive interim Phase II trial safety and immunogenicity data for the Canadian company\u00e2\u0080\u0099s plant-de", "link": "https://www.thepharmaletter.com/article/phase-ii-success-for-plant-based-vaccine-from-medicago-and-gsk", "pubDate": "2021-05-18 14:31:00"}, {"filename": "hummingbird-bioscience-raises-125-million-financing.json", "title": "Hummingbird Bioscience raises $125 million financing", "description": "Hummingbird Bioscience raises $125 million financing", "link": "https://www.thepharmaletter.com/article/hummingbird-bioscience-raises-125-million-financing", "pubDate": "2021-05-18 14:06:00"}, {"filename": "merck-revokes-registration-for-its-next-generation-sleeping-pill-belsomra-in-russia.json", "title": "Merck revokes registration for its next-generation sleeping pill Belsomra in Russia", "description": "Merck revokes registration for its next-generation sleeping pill Belsomra in Russia", "link": "https://www.thepharmaletter.com/article/merck-revokes-registration-for-its-next-generation-sleeping-pill-belsomra-in-russia", "pubDate": "2021-05-18 12:26:00"}, {"filename": "r-pharm-to-produce-astrazeneca-vaccine-in-russia.json", "title": "R-Pharm to produce AstraZeneca vaccine in Russia", "description": "R-Pharm to produce AstraZeneca vaccine in Russia", "link": "https://www.thepharmaletter.com/article/r-pharm-to-produce-astrazeneca-vaccine-in-russia", "pubDate": "2021-05-18 11:43:00"}, {"filename": "us-supreme-court-denies-sandoz-petition-to-review-biosimilar-erelzi-case.json", "title": "US Supreme Court denies Sandoz petition to review biosimilar Erelzi case", "description": "US Supreme Court denies Sandoz petition to review biosimilar Erelzi case", "link": "https://www.thepharmaletter.com/article/us-supreme-court-denies-sandoz-petition-to-review-biosimilar-erelzi-case", "pubDate": "2021-05-18 10:46:00"}, {"filename": "biomay-cooperates-with-biontech-on-covid-19-mrna-vaccine.json", "title": "Biomay cooperates with BioNTech on COVID-19 mRNA vaccine", "description": "Biomay cooperates with BioNTech on COVID-19 mRNA vaccine", "link": "https://www.thepharmaletter.com/article/biomay-cooperates-with-biontech-on-covid-19-mrna-vaccine", "pubDate": "2021-05-18 10:14:00"}, {"filename": "fda-approves-empaveli-for-life-threatening-rare-blood-disease.json", "title": "FDA approves Empaveli for life-threatening rare blood disease", "description": "FDA approves Empaveli for life-threatening rare blood disease", "link": "https://www.thepharmaletter.com/article/fda-approves-empaveli-for-life-threatening-rare-blood-disease", "pubDate": "2021-05-18 10:14:00"}, {"filename": "greek-trade-group-sfee-reports-on-6th-delphi-economic-forum.json", "title": "Greek trade group SFEE reports on 6th Delphi Economic Forum", "description": "Greek trade group SFEE reports on 6th Delphi Economic Forum", "link": "https://www.thepharmaletter.com/article/greek-trade-group-sfee-reports-on-6th-delphi-economic-forum", "pubDate": "2021-05-17 17:11:00"}, {"filename": "dupixent-on-a-roll-with-more-positive-data.json", "title": "Dupixent on a roll with more positive data", "description": "Sanofi has presented detailed results from the Phase III VOYAGE trial, showing that Dupixent (dupilumab) significantly reduced severe asthma attacks, and within", "link": "https://www.thepharmaletter.com/article/dupixent-on-a-roll-with-more-positive-data", "pubDate": "2021-05-17 17:03:00"}, {"filename": "entresto-data-disappoint-at-annual-meeting-of-aac.json", "title": "Entresto data disappoint at annual meeting of ACC", "description": "At the annual meeting of the American College of Cardiology (ACC), poor results for Novartis\u00e2\u0080\u0099 Entresto (sacubitril/valsartan) have disappointed.", "link": "https://www.thepharmaletter.com/article/entresto-data-disappoint-at-annual-meeting-of-aac", "pubDate": "2021-05-17 14:24:00"}, {"filename": "trial-results-for-farxiga-in-covid-19-detailed-at-acc-2021.json", "title": "Trial results for Farxiga in COVID-19 detailed at ACC 2021", "description": "Detailed results from the Phase III DARE-19 trial, testing AstraZeneca's (LSE: AZN) SGLT2 blocker Farxiga (dapagliflozin) in COVID-19, show no significant benef", "link": "https://www.thepharmaletter.com/article/trial-results-for-farxiga-in-covid-19-detailed-at-acc-2021", "pubDate": "2021-05-17 14:12:00"}, {"filename": "positive-data-for-mavacamten-former-myokardia-lead-asset.json", "title": "Positive data for mavacamten, former MyoKardia lead asset", "description": "Bristol Myers Squibb has announced a new analysis of data from the Phase III EXPLORER-HCM study of mavacamten, the firm\u00e2\u0080\u0099s investigational, first-in-class cardia", "link": "https://www.thepharmaletter.com/article/positive-data-for-mavacamten-former-myokardia-lead-asset", "pubDate": "2021-05-17 12:06:00"}, {"filename": "sanofi-gsk-jab-set-to-move-into-phase-iii-trial.json", "title": "Sanofi-GSK jab set to move into Phase III trial", "description": "A Phase II study of the coronavirus vaccine under development by Sanofi (Euronext: SAN) and GlaxoSmithKline (LSE: GSK) has shown the jab achieved strong rates o", "link": "https://www.thepharmaletter.com/article/sanofi-gsk-jab-set-to-move-into-phase-iii-trial", "pubDate": "2021-05-17 10:48:00"}, {"filename": "trips-waiver-is-the-us-backing-a-cause-for-concern-for-pharma.json", "title": "TRIPS waiver: Is the US backing a cause for concern for pharma?", "description": "The mere notion of the US government supporting any policies that might encourage pharmaceutical patents to be ignored would have seemed inconceivable only 18 m", "link": "https://www.thepharmaletter.com/article/trips-waiver-is-the-us-backing-a-cause-for-concern-for-pharma", "pubDate": "2021-05-17 10:02:00"}, {"filename": "look-back-at-pharma-news-in-the-week-to-may-14-2021.json", "title": "Look back at pharma news in the week to May 14, 2021", "description": "Look back at pharma news in the week to May 14, 2021", "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-may-14-2021", "pubDate": "2021-05-16 10:50:00"}, {"filename": "disappointing-results-from-biogen-s-gene-therapy-study-for-xlrp.json", "title": "Disappointing results from Biogen\u00e2\u0080\u0099s gene therapy study for XLRP", "description": "Disappointing results from Biogen\u00e2\u0080\u0099s gene therapy study for XLRP", "link": "https://www.thepharmaletter.com/article/disappointing-results-from-biogen-s-gene-therapy-study-for-xlrp", "pubDate": "2021-05-15 15:45:00"}, {"filename": "viatris-1st-qtr-2021-financials-beat-expectations.json", "title": "Viatris\u00e2\u0080\u0099 1st-qtr 2021 financials beat expectations", "description": "Viatris\u00e2\u0080\u0099 1st-qtr 2021 financials beat expectations", "link": "https://www.thepharmaletter.com/article/viatris-1st-qtr-2021-financials-beat-expectations", "pubDate": "2021-05-15 14:41:00"}, {"filename": "positive-data-on-ofev-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease.json", "title": "Positive data on Ofev in patients with systemic sclerosis-associated interstitial lung disease", "description": "Positive data on Ofev in patients with systemic sclerosis-associated interstitial lung disease", "link": "https://www.thepharmaletter.com/article/positive-data-on-ofev-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease", "pubDate": "2021-05-14 15:52:00"}, {"filename": "abbvie-confident-of-fighting-off-alvotech-challenge-on-humira.json", "title": "AbbVie confident of fighting off Alvotech challenge on Humira", "description": "US pharma major AbbVie has answered back in its latest row over Humira (adalimumab), the inflammatory diseases drug that it continues to sell without competitio", "link": "https://www.thepharmaletter.com/article/abbvie-confident-of-fighting-off-alvotech-challenge-on-humira", "pubDate": "2021-05-14 15:15:00"}, {"filename": "nice-backs-keytruda-for-nhs-us-in-a-subtype-of-colorectal-cancer.json", "title": "NICE backs Keytruda for NHS use in a subtype of colorectal cancer", "description": "NICE backs Keytruda for NHS use in a subtype of colorectal cancer", "link": "https://www.thepharmaletter.com/article/nice-backs-keytruda-for-nhs-us-in-a-subtype-of-colorectal-cancer", "pubDate": "2021-05-14 14:08:00"}, {"filename": "responsible-supply-chains-to-combat-growing-public-health-threats.json", "title": "Responsible supply chains to combat growing public health threats", "description": "An Expert View from Manjit Singh, chairman of the Pharmaceutical Supply Chain Initiative, which tries to foster responsible supply chains, highlighting the issu", "link": "https://www.thepharmaletter.com/article/responsible-supply-chains-to-combat-growing-public-health-threats", "pubDate": "2021-05-14 12:41:00"}, {"filename": "faron-sub-licenses-us-rights-to-traumakine-patent.json", "title": "Faron sub-licenses US rights to traumakine patent", "description": "Faron sub-licenses US rights to traumakine patent", "link": "https://www.thepharmaletter.com/article/faron-sub-licenses-us-rights-to-traumakine-patent", "pubDate": "2021-05-14 12:20:00"}, {"filename": "benefit-of-aligning-to-gold-recommendations-in-copd-treatment.json", "title": "Benefit of aligning to GOLD recommendations in COPD treatment", "description": "Benefit of aligning to GOLD recommendations in COPD treatment", "link": "https://www.thepharmaletter.com/article/benefit-of-aligning-to-gold-recommendations-in-copd-treatment", "pubDate": "2021-05-14 12:03:00"}, {"filename": "novel-glaucoma-med-eyes-once-daily-dosing-regimen.json", "title": "Novel glaucoma med targets once-daily dosing regimen", "description": "Mumbai\u00e2\u0080\u0099s Sun Pharma Advanced Research Company has reported positive topline data from a Phase III trial of investigational eye drug PDP-716.", "link": "https://www.thepharmaletter.com/article/novel-glaucoma-med-eyes-once-daily-dosing-regimen", "pubDate": "2021-05-14 11:05:00"}, {"filename": "india-s-bharat-biotech-to-share-its-covid-vaccine-code-with-other-drug-firms.json", "title": "India's Bharat Biotech to share its Covid vaccine code with other drug firms", "description": "India's Bharat Biotech to share its Covid vaccine code with other drug firms", "link": "https://www.thepharmaletter.com/article/india-s-bharat-biotech-to-share-its-covid-vaccine-code-with-other-drug-firms", "pubDate": "2021-05-14 10:45:00"}, {"filename": "fda-guidance-m9-biopharmaceutics-classification-system-based-biowaivers.json", "title": "FDA guidance: M9 biopharmaceutics classification system-based biowaivers", "description": "FDA guidance: M9 biopharmaceutics classification system-based biowaivers", "link": "https://www.thepharmaletter.com/article/fda-guidance-m9-biopharmaceutics-classification-system-based-biowaivers", "pubDate": "2021-05-14 10:27:00"}, {"filename": "caris-life-sciences-raises-830-million-in-growth-equity-capital.json", "title": "Caris Life Sciences raises $830 million in growth equity capital", "description": "Caris Life Sciences raises $830 million in growth equity capital", "link": "https://www.thepharmaletter.com/article/caris-life-sciences-raises-830-million-in-growth-equity-capital", "pubDate": "2021-05-14 10:19:00"}, {"filename": "fda-accepts-strongbridge-s-recorlev-nda-for-review.json", "title": "FDA accepts Strongbridge\u00e2\u0080\u0099s Recorlev NDA for review", "description": "FDA accepts Strongbridge\u00e2\u0080\u0099s Recorlev NDA for review", "link": "https://www.thepharmaletter.com/article/fda-accepts-strongbridge-s-recorlev-nda-for-review", "pubDate": "2021-05-13 16:58:00"}, {"filename": "phase-iii-success-for-keytruda-combo-in-breast-cancer.json", "title": "Phase III success for Keytruda combo in breast cancer", "description": "Merck & Co's checkpoint blocker and commercial super-blockbuster Keytruda (pembrolizumab) has scored another Phase III success, in triple-negative breast cancer", "link": "https://www.thepharmaletter.com/article/phase-iii-success-for-keytruda-combo-in-breast-cancer", "pubDate": "2021-05-13 14:56:00"}, {"filename": "hope-b-clinical-data-shows-clinical-benefit-of-uniqure-drug-in-hemophilia-b-patients.json", "title": "HOPE-B clinical data shows clinical benefit of uniQure drug in hemophilia B patients", "description": "HOPE-B clinical data shows clinical benefit of uniQure drug in hemophilia B patients", "link": "https://www.thepharmaletter.com/article/hope-b-clinical-data-shows-clinical-benefit-of-uniqure-drug-in-hemophilia-b-patients", "pubDate": "2021-05-13 14:46:00"}, {"filename": "nice-backs-opdivo-as-first-immunotherapy-for-patients-in-england-with-oscc.json", "title": "NICE backs Opdivo as first immunotherapy for patients in England with OSCC", "description": "NICE backs Opdivo as first immunotherapy for patients in England with OSCC", "link": "https://www.thepharmaletter.com/article/nice-backs-opdivo-as-first-immunotherapy-for-patients-in-england-with-oscc", "pubDate": "2021-05-13 13:53:00"}, {"filename": "mixing-covid-19-vaccines-leads-to-more-frequent-reactions-study-shows.json", "title": "Mixing COVID-19 vaccines leads to more frequent reactions, study shows", "description": "The University of Oxford-led Com-COV study \u00e2\u0080\u0093 launched to investigate alternating doses of the Oxford-AstraZeneca vaccine and the jab from Pfizer and BioNTech \u00e2\u0080\u0093 ", "link": "https://www.thepharmaletter.com/article/mixing-covid-19-vaccines-leads-to-more-frequent-reactions-study-shows", "pubDate": "2021-05-13 12:46:00"}, {"filename": "us-cdc-recommends-use-of-pfizer-biontech-jab-in-adolescents.json", "title": "US CDC recommends use of Pfizer-BioNTech jab in adolescents", "description": "The US Centers for Disease Control and Prevention (CDC) has formally recommended use of Comirnaty - the coronavirus vaccine developed by BioNTech and Pfizer - i", "link": "https://www.thepharmaletter.com/article/us-cdc-recommends-use-of-pfizer-biontech-jab-in-adolescents", "pubDate": "2021-05-13 12:19:00"}, {"filename": "new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-population-of-severe-asthma-patients.json", "title": "New tezepelumab data continue to strengthen profile for a broad population of severe asthma patients", "description": "New tezepelumab data continue to strengthen profile for a broad population of severe asthma patients", "link": "https://www.thepharmaletter.com/article/new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-population-of-severe-asthma-patients", "pubDate": "2021-05-13 12:13:00"}, {"filename": "curis-rockets-on-release-of-data-for-ca-4948-in-aml-and-mds.json", "title": "Curis rockets on release of data for CA-4948 in AML and MDS", "description": "Curis rockets on release of data for CA-4948 in AML and MDS", "link": "https://www.thepharmaletter.com/article/curis-rockets-on-release-of-data-for-ca-4948-in-aml-and-mds", "pubDate": "2021-05-13 11:30:00"}, {"filename": "discount-checkpoint-blocker-aims-to-disrupt-market.json", "title": "Discount checkpoint blocker aims to disrupt market", "description": "New York\u00e2\u0080\u0099s Checkpoint Therapeutics has finished enrolling patients in a registration-enabling trial of its experimental checkpoint blocker cosibelimab.", "link": "https://www.thepharmaletter.com/article/discount-checkpoint-blocker-aims-to-disrupt-market", "pubDate": "2021-05-13 11:00:00"}, {"filename": "positive-libtayo-phase-iii-data-in-advanced-cervical-cancer.json", "title": "Positive Libtayo Phase III data in advanced cervical cancer", "description": "Positive Libtayo Phase III data in advanced cervical cancer", "link": "https://www.thepharmaletter.com/article/positive-libtayo-phase-iii-data-in-advanced-cervical-cancer", "pubDate": "2021-05-13 10:35:00"}, {"filename": "nice-decides-not-to-recommend-ozanimod-for-people-with-relapsing-ms-on-the-nhs.json", "title": "NICE decides not to recommend ozanimod for people with relapsing MS on the NHS", "description": "NICE decides not to recommend ozanimod for people with relapsing MS on the NHS", "link": "https://www.thepharmaletter.com/article/nice-decides-not-to-recommend-ozanimod-for-people-with-relapsing-ms-on-the-nhs", "pubDate": "2021-05-13 10:26:00"}, {"filename": "genentech-s-swati-tole-named-cmo-at-capsida.json", "title": "Genentech\u00e2\u0080\u0099s Swati Tole named CMO at Capsida", "description": NaN, "link": "https://www.thepharmaletter.com/article/genentech-s-swati-tole-named-cmo-at-capsida", "pubDate": "2021-05-12 18:00:00"}, {"filename": "uk-s-cat-upholds-decision-on-gsk-pay-for-delay-pharma-deals.json", "title": "UK\u00e2\u0080\u0099s CAT upholds decision on GSK pay-for-delay pharma deals", "description": "UK\u00e2\u0080\u0099s CAT upholds decision on GSK pay-for-delay pharma deals", "link": "https://www.thepharmaletter.com/article/uk-s-cat-upholds-decision-on-gsk-pay-for-delay-pharma-deals", "pubDate": "2021-05-12 16:27:00"}, {"filename": "biogen-buys-rights-to-investigational-game-changing-stroke-drug.json", "title": "Biogen buys rights to investigational \u00e2\u0080\u0098game-changing\u00e2\u0080\u0099 stroke drug", "description": "Biogen buys rights to investigational \u00e2\u0080\u0098game-changing\u00e2\u0080\u0099 stroke drug", "link": "https://www.thepharmaletter.com/article/biogen-buys-rights-to-investigational-game-changing-stroke-drug", "pubDate": "2021-05-12 15:38:00"}, {"filename": "merck-kgaa-confirms-positive-quarter-and-promises-sustainable-growth.json", "title": "Merck KGaA confirms positive quarter and promises \u00e2\u0080\u0098sustainable growth\u00e2\u0080\u0099", "description": NaN, "link": "https://www.thepharmaletter.com/article/merck-kgaa-confirms-positive-quarter-and-promises-sustainable-growth", "pubDate": "2021-05-12 15:05:00"}, {"filename": "diurnal-expands-deal-with-citrine-medicine-for-efmody.json", "title": "Diurnal expands deal with Citrine Medicine for Efmody", "description": "Diurnal expands deal with Citrine Medicine for Efmody", "link": "https://www.thepharmaletter.com/article/diurnal-expands-deal-with-citrine-medicine-for-efmody", "pubDate": "2021-05-12 14:35:00"}, {"filename": "alvotech-takes-on-might-of-abbvie-s-humira-armory.json", "title": "Alvotech takes on might of AbbVie\u00e2\u0080\u0099s Humira armory", "description": NaN, "link": "https://www.thepharmaletter.com/article/alvotech-takes-on-might-of-abbvie-s-humira-armory", "pubDate": "2021-05-12 12:49:00"}, {"filename": "biogen-forking-out-1-3-billion-on-aav-capsids-deal.json", "title": "Biogen forking out $1.3 billion on AAV capsids deal", "description": "Biogen forking out $1.3 billion on AAV capsids deal", "link": "https://www.thepharmaletter.com/article/biogen-forking-out-1-3-billion-on-aav-capsids-deal", "pubDate": "2021-05-12 12:33:00"}, {"filename": "cabometyx-continues-to-show-promise-for-ipsen-and-exelixis.json", "title": "Cabometyx continues to show promise for Ipsen and Exelixis", "description": "Parisian biotech has exercised an option to collaborate with Exelixis (Nasdaq: EXEL) on further development of Cabometyx (cabozantinib) in thyroid cancer.", "link": "https://www.thepharmaletter.com/article/cabometyx-continues-to-show-promise-for-ipsen-and-exelixis", "pubDate": "2021-05-12 12:13:00"}, {"filename": "lundbeck-rises-as-1st-qtr-beats-forecasts.json", "title": "Lundbeck rises as 1st-qtr beats forecasts", "description": "Lundbeck rises as 1st-qtr beats forecasts", "link": "https://www.thepharmaletter.com/article/lundbeck-rises-as-1st-qtr-beats-forecasts", "pubDate": "2021-05-12 11:36:00"}, {"filename": "bayer-reports-financial-results-for-first-quarter.json", "title": "Bayer lifted after first quarter financial results", "description": "Reporting first-quarter financial results, Leverkusen-based Bayer said sales of pharmaceuticals came in at 4.4 billion euros ($5.3 billion), a 4% fall from the ", "link": "https://www.thepharmaletter.com/article/bayer-reports-financial-results-for-first-quarter", "pubDate": "2021-05-12 10:48:00"}, {"filename": "ftc-multilateral-pharma-merger-task-force-seeks-public-input.json", "title": "FTC multilateral pharma merger task force seeks public input", "description": "FTC multilateral pharma merger task force seeks public input", "link": "https://www.thepharmaletter.com/article/ftc-multilateral-pharma-merger-task-force-seeks-public-input", "pubDate": "2021-05-12 10:33:00"}, {"filename": "findings-of-icer-final-evidence-report-for-multiple-myeloma-therapies.json", "title": "Findings of ICER Final Evidence Report for multiple myeloma therapies", "description": "Findings of ICER Final Evidence Report for multiple myeloma therapies", "link": "https://www.thepharmaletter.com/article/findings-of-icer-final-evidence-report-for-multiple-myeloma-therapies", "pubDate": "2021-05-12 10:20:00"}, {"filename": "mina-therapeutics-picks-up-another-sarna-research-deal.json", "title": "MiNA Therapeutics picks up another saRNA research deal", "description": "MiNA Therapeutics picks up another saRNA research deal", "link": "https://www.thepharmaletter.com/article/mina-therapeutics-picks-up-another-sarna-research-deal", "pubDate": "2021-05-11 16:33:00"}, {"filename": "pakistan-oks-compassionate-use-of-zofin-for-covid-19.json", "title": "Pakistan OKs compassionate use of Zofin for COVID-19", "description": "Pakistan OKs compassionate use of Zofin for COVID-19", "link": "https://www.thepharmaletter.com/article/pakistan-oks-compassionate-use-of-zofin-for-covid-19", "pubDate": "2021-05-11 15:55:00"}, {"filename": "inovio-edging-forward-with-covid-19-vaccine.json", "title": "Inovio edging forward with COVID-19 vaccine", "description": "US biotech Inovio might be behind competitors in the development of a COVID-19 vaccine, but the company has provided a reminder that it is still in the game.", "link": "https://www.thepharmaletter.com/article/inovio-edging-forward-with-covid-19-vaccine", "pubDate": "2021-05-11 14:51:00"}, {"filename": "takeda-delivers-resilient-fy2020-financials.json", "title": "Takeda delivers resilient FY2020 financials", "description": "Takeda delivers resilient FY2020 financials", "link": "https://www.thepharmaletter.com/article/takeda-delivers-resilient-fy2020-financials", "pubDate": "2021-05-11 14:07:00"}, {"filename": "new-biotechs-see-practice-changing-potential-of-psychedelics.json", "title": "New biotechs see practice-changing potential in psychedelics", "description": NaN, "link": "https://www.thepharmaletter.com/article/new-biotechs-see-practice-changing-potential-of-psychedelics", "pubDate": "2021-05-11 12:23:00"}, {"filename": "bayer-s-finerenone-meets-primary-goal-in-phase-iii.json", "title": "Bayer\u00e2\u0080\u0099s finerenone meets primary goal in Phase III", "description": "Bayer\u00e2\u0080\u0099s finerenone meets primary goal in Phase III", "link": "https://www.thepharmaletter.com/article/bayer-s-finerenone-meets-primary-goal-in-phase-iii", "pubDate": "2021-05-11 12:05:00"}, {"filename": "fda-nod-for-emergency-use-of-pfizer-biontech-covid-19-vaccine-in-adolescents.json", "title": "FDA nod for emergency use of Pfizer-BioNTech COVID-19 Vaccine in adolescents", "description": "FDA nod for emergency use of Pfizer-BioNTech COVID-19 Vaccine in adolescents", "link": "https://www.thepharmaletter.com/article/fda-nod-for-emergency-use-of-pfizer-biontech-covid-19-vaccine-in-adolescents", "pubDate": "2021-05-11 10:58:00"}, {"filename": "third-quarter-submission-now-looks-likely-for-novavax-vaccine.json", "title": "Third-quarter submission now looks likely for Novavax", "description": "Slow progress in preparing regulatory submissions will see US vaccines developer Novavax send its COVID-19 vaccine, NVX-CoV2373, for approval in the third quart", "link": "https://www.thepharmaletter.com/article/third-quarter-submission-now-looks-likely-for-novavax-vaccine", "pubDate": "2021-05-11 10:49:00"}, {"filename": "global-insulin-producers-losing-positions-0in-russian-market.json", "title": "Global insulin producers losing positions in Russian market", "description": "Global insulin producers losing positions 0in Russian marke", "link": "https://www.thepharmaletter.com/article/global-insulin-producers-losing-positions-0in-russian-market", "pubDate": "2021-05-11 10:32:00"}, {"filename": "almirall-closes-8-higher-as-sales-beat-estimates.json", "title": "Almirall closes 8% higher as sales beat estimates", "description": "Spanish dermatology specialist Almirall closed 8% higher on Monday after presenting its first quarter financial results.", "link": "https://www.thepharmaletter.com/article/almirall-closes-8-higher-as-sales-beat-estimates", "pubDate": "2021-05-10 19:03:00"}, {"filename": "sumitomo-dainippon-acquires-asian-rights-for-sinovant-compounds.json", "title": "Sumitomo Dainippon acquires Asian rights for Sinovant compounds", "description": "Japanese pharma company Sumitomo Dainippon Pharma is to acquire the exclusive development and marketing rights in China, Hong Kong, Taiwan and other Asian marke", "link": "https://www.thepharmaletter.com/article/sumitomo-dainippon-acquires-asian-rights-for-sinovant-compounds", "pubDate": "2021-05-10 18:00:00"}, {"filename": "russian-government-to-provide-subsidies-to-domestic-drug-exporters.json", "title": "Russian government to provide subsidies to domestic drug exporters", "description": "Russian government to provide subsidies to domestic drug exporters", "link": "https://www.thepharmaletter.com/article/russian-government-to-provide-subsidies-to-domestic-drug-exporters", "pubDate": "2021-05-10 16:50:00"}, {"filename": "abingworth-raises-582-million-for-fund-supporting-late-stage-research.json", "title": "Abingworth raises $582 million for fund supporting late-stage research", "description": "Life sciences investment group Abingworth has announced the final closing of its new Clinical Co-Development Fund at $582 million.", "link": "https://www.thepharmaletter.com/article/abingworth-raises-582-million-for-fund-supporting-late-stage-research", "pubDate": "2021-05-10 16:22:00"}, {"filename": "lilly-inks-licensing-pacts-with-indian-drugmakers-for-baricitinib.json", "title": "Lilly inks licensing pacts with Indian drugmakers for baricitinib", "description": "Lilly inks licensing pacts with Indian drugmakers for baricitinib", "link": "https://www.thepharmaletter.com/article/lilly-inks-licensing-pacts-with-indian-drugmakers-for-baricitinib", "pubDate": "2021-05-10 13:55:00"}, {"filename": "biontech-keeps-growing-with-singapore-based-site.json", "title": "BioNTech keeps growing with Singapore-based site", "description": "Mainz, Germany-based BioNTech has announced plans to expand its global footprint to Asia with the establishment of a new regional headquarters in Singapore.", "link": "https://www.thepharmaletter.com/article/biontech-keeps-growing-with-singapore-based-site", "pubDate": "2021-05-10 13:09:00"}, {"filename": "chugai-deal-with-japanese-govt-on-antibody-cocktail-for-covid-19.json", "title": "Chugai deal with Japanese govt on antibody cocktail for COVID-19", "description": "Chugai deal with Japanese govt on antibody cocktail for COVID-19", "link": "https://www.thepharmaletter.com/article/chugai-deal-with-japanese-govt-on-antibody-cocktail-for-covid-19", "pubDate": "2021-05-10 12:37:00"}, {"filename": "knife-edge-panel-vote-puts-vasculitis-treatment-in-doubt.json", "title": "Knife-edge panel vote puts vasculitis treatment in doubt", "description": "An evenly split vote from the US regulator\u00e2\u0080\u0099s scientific panel sent shares in California\u00e2\u0080\u0099s ChemoCentryx into free fall on Friday.", "link": "https://www.thepharmaletter.com/article/knife-edge-panel-vote-puts-vasculitis-treatment-in-doubt", "pubDate": "2021-05-10 11:30:00"}, {"filename": "ec-approval-for-xtandi-in-mhs-prostate-cancer.json", "title": "EC approval for Xtandi in mHS prostate cancer", "description": "EC approval for Xtandi in mHS prostate cancer", "link": "https://www.thepharmaletter.com/article/ec-approval-for-xtandi-in-mhs-prostate-cancer", "pubDate": "2021-05-10 11:25:00"}, {"filename": "galapagos-refocuses-pipeline.json", "title": "Galapagos refocuses pipeline", "description": "Galapagos refocuses pipeline", "link": "https://www.thepharmaletter.com/article/galapagos-refocuses-pipeline", "pubDate": "2021-05-10 11:18:00"}, {"filename": "who-lists-sinopharm-s-covid-19-vaccine-for-emergency-use.json", "title": "WHO lists Sinopharm\u00e2\u0080\u0099s COVID-19 vaccine for emergency use", "description": "WHO lists Sinopharm\u00e2\u0080\u0099s COVID-19 vaccine for emergency use", "link": "https://www.thepharmaletter.com/article/who-lists-sinopharm-s-covid-19-vaccine-for-emergency-use", "pubDate": "2021-05-10 11:17:00"}, {"filename": "look-back-at-pharma-news-in-the-week-to-may-7-2021.json", "title": "Look back at pharma news in the week to May 7, 2021", "description": "Look back at pharma news in the week to May 7, 2021", "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-may-7-2021", "pubDate": "2021-05-09 10:52:00"}, {"filename": "china-nmpa-conditional-nod-for-pamiparib-in-ovarian-cancer.json", "title": "China NMPA conditional nod for pamiparib in ovarian cancer", "description": "China NMPA conditional nod for pamiparib in ovarian cancer", "link": "https://www.thepharmaletter.com/article/china-nmpa-conditional-nod-for-pamiparib-in-ovarian-cancer", "pubDate": "2021-05-08 15:28:00"}, {"filename": "the-continuing-quest-to-get-more-women-on-life-sciences-boards.json", "title": "The continuing quest to get more women on life sciences boards", "description": "Catherine Owen, senior vice president of major markets at Bristol Myers Squibb, provides an Expert View on why increasing female representation on corporate boa", "link": "https://www.thepharmaletter.com/article/the-continuing-quest-to-get-more-women-on-life-sciences-boards", "pubDate": "2021-05-07 18:14:00"}, {"filename": "santen-powers-on-with-blepharitis-gel-launches.json", "title": "Santen powers on with blepharitis gel launches", "description": "Japanese opthalmology specialist Santen has now ticked off much of Europe with its launch of Puralid Lipogel, an ophthalmic gel for blepharitis.", "link": "https://www.thepharmaletter.com/article/santen-powers-on-with-blepharitis-gel-launches", "pubDate": "2021-05-07 17:12:00"}, {"filename": "mhra-grants-license-extension-for-tagrisso-in-specific-type-of-lung-cancer.json", "title": "MHRA grants license extension for Tagrisso in specific type of lung cancer", "description": "AstraZeneca\u00e2\u0080\u0099s Tagrisso (osimertinib) is the beneficiary of the UK\u00e2\u0080\u0099s Medicines and Healthcare products Regulatory Agency\u00e2\u0080\u0099s (MHRA) first authorization under Proje", "link": "https://www.thepharmaletter.com/article/mhra-grants-license-extension-for-tagrisso-in-specific-type-of-lung-cancer", "pubDate": "2021-05-07 17:03:00"}, {"filename": "eu-strategy-for-the-development-and-availability-of-therapeutics.json", "title": "EU Strategy for the development and availability of therapeutics", "description": "EU Strategy for the development and availability of therapeutics", "link": "https://www.thepharmaletter.com/article/eu-strategy-for-the-development-and-availability-of-therapeutics", "pubDate": "2021-05-07 16:44:00"}, {"filename": "pfizer-and-biontech-initiate-fda-rolling-bla-submission-for-their-covid-19-vaccine.json", "title": "Pfizer and BioNTech initiate FDA rolling BLA submission for their COVID-19 vaccine", "description": "Pfizer and BioNTech initiate FDA rolling BLA submission for their COVID-19 vaccine", "link": "https://www.thepharmaletter.com/article/pfizer-and-biontech-initiate-fda-rolling-bla-submission-for-their-covid-19-vaccine", "pubDate": "2021-05-07 15:48:00"}, {"filename": "march-april-2021-pharmaceutical-m-a-round-up.json", "title": "March & April 2021 pharmaceutical M&A round-up", "description": "Some of biopharma's biggest companies announced acquisitions in March and April.", "link": "https://www.thepharmaletter.com/article/march-april-2021-pharmaceutical-m-a-round-up", "pubDate": "2021-05-07 15:02:00"}, {"filename": "european-regulator-reiterates-safety-of-coronavirus-vaccines.json", "title": "European regulator reiterates safety of coronavirus vaccines", "description": "Minutes from the May meeting of the European Medicines Agency\u00e2\u0080\u0099s safety committee show the panel has reaffirmed the positive benefit-risk ratio of approved coron", "link": "https://www.thepharmaletter.com/article/european-regulator-reiterates-safety-of-coronavirus-vaccines", "pubDate": "2021-05-07 14:26:00"}, {"filename": "ema-starts-rolling-review-of-sotrovimab-for-early-treatment-of-covid-19.json", "title": "EMA starts rolling review of sotrovimab for early treatment of COVID-19", "description": "EMA starts rolling review of sotrovimab for early treatment of COVID-19", "link": "https://www.thepharmaletter.com/article/ema-starts-rolling-review-of-sotrovimab-for-early-treatment-of-covid-19", "pubDate": "2021-05-07 13:50:00"}, {"filename": "jcvi-advises-on-covid-19-vaccine-for-under-40-year-olds.json", "title": "JCVI advises on COVID-19 vaccine for under 40-year-olds", "description": "JCVI advises on COVID-19 vaccine for under 40-year-olds", "link": "https://www.thepharmaletter.com/article/jcvi-advises-on-covid-19-vaccine-for-under-40-year-olds", "pubDate": "2021-05-07 12:17:00"}, {"filename": "international-regulators-and-who-call-for-wider-public-access-to-clinical-data.json", "title": "International regulators and WHO call for wider public access to clinical data", "description": "International regulators and WHO call for wider public access to clinical data", "link": "https://www.thepharmaletter.com/article/international-regulators-and-who-call-for-wider-public-access-to-clinical-data", "pubDate": "2021-05-07 11:42:00"}, {"filename": "coronavirus-antibody-cocktail-lifts-regeneron-in-first-quarter.json", "title": "Coronavirus cocktail boosts Regeneron in first quarter", "description": "An estimate-beating first quarter performance lifted shares in New York\u00e2\u0080\u0099s Regeneron Pharmaceuticals over 3% on Thursday, with revenues up 38% at $2.5 billion.", "link": "https://www.thepharmaletter.com/article/coronavirus-antibody-cocktail-lifts-regeneron-in-first-quarter", "pubDate": "2021-05-07 11:16:00"}, {"filename": "crispr-therapeutics-inks-deal-with-nkarta-on-gene-edited-cell-therapies-for-cancer.json", "title": "CRISPR Therapeutics inks deal with Nkarta on gene-edited cell therapies for cancer", "description": "CRISPR Therapeutics inks deal with Nkarta on gene-edited cell therapies for cancer", "link": "https://www.thepharmaletter.com/article/crispr-therapeutics-inks-deal-with-nkarta-on-gene-edited-cell-therapies-for-cancer", "pubDate": "2021-05-07 10:54:00"}, {"filename": "imfinzi-tremelimumab-showed-improved-survival-in-poseidon-trial.json", "title": "Imfinzi + tremelimumab showed improved survival in POSEIDON trial", "description": "Imfinzi + tremelimumab showed improved survival in POSEIDON trial", "link": "https://www.thepharmaletter.com/article/imfinzi-tremelimumab-showed-improved-survival-in-poseidon-trial", "pubDate": "2021-05-07 10:15:00"}, {"filename": "what-a-difference-a-year-makes-for-moderna.json", "title": "What a difference a year makes for Moderna", "description": "A 23,650% first quarter revenue increase makes clear the level of fiscal impact a successful coronavirus vaccine can have.", "link": "https://www.thepharmaletter.com/article/what-a-difference-a-year-makes-for-moderna", "pubDate": "2021-05-06 17:10:00"}, {"filename": "impressive-phase-iib-data-for-moonlake-s-sonelokimab.json", "title": "Impressive Phase IIb data for MoonLake\u00e2\u0080\u0099s sonelokimab", "description": "Impressive Phase IIb data for MoonLake\u00e2\u0080\u0099s sonelokimab", "link": "https://www.thepharmaletter.com/article/impressive-phase-iib-data-for-moonlake-s-sonelokimab", "pubDate": "2021-05-06 16:19:00"}, {"filename": "lonza-expands-manufacturing-in-visp-switz-and-portsmouth-usa.json", "title": "Lonza expands manufacturing in Visp (Switz) and Portsmouth (USA)", "description": "Lonza expands manufacturing in Visp (Switz) and Portsmouth (USA)", "link": "https://www.thepharmaletter.com/article/lonza-expands-manufacturing-in-visp-switz-and-portsmouth-usa", "pubDate": "2021-05-06 15:44:00"}, {"filename": "first-quarter-sales-and-earnings-down-at-recordati.json", "title": "First-quarter sales and earnings down at Recordati", "description": "First-quarter sales and earnings down at Recordati", "link": "https://www.thepharmaletter.com/article/first-quarter-sales-and-earnings-down-at-recordati", "pubDate": "2021-05-06 15:16:00"}, {"filename": "icer-questions-aducanumab-s-health-benefit-in-early-price-review.json", "title": "ICER questions aducanumab\u00e2\u0080\u0099s health benefit in early price review", "description": "The Institute for Clinical and Economic Review (ICER) has released a draft evidence report assessing the comparative clinical effectiveness and value of aducanu", "link": "https://www.thepharmaletter.com/article/icer-questions-aducanumab-s-health-benefit-in-early-price-review", "pubDate": "2021-05-06 12:46:00"}, {"filename": "us-u-turn-could-see-coronavirus-vaccine-patents-set-aside.json", "title": "US U-turn could see coronavirus vaccine patents set aside", "description": "To the surprise of many, the US Government has backed a World Trade Organization (WTO) proposal to disclaim certain intellectual property (IP) rights to coronav", "link": "https://www.thepharmaletter.com/article/us-u-turn-could-see-coronavirus-vaccine-patents-set-aside", "pubDate": "2021-05-06 12:39:00"}, {"filename": "vectura-and-inspira-to-develop-potential-inhaled-covid-19-treatment.json", "title": "Vectura and Inspira to develop potential inhaled COVID-19 treatment", "description": "Vectura and Inspira to develop potential inhaled COVID-19 treatment", "link": "https://www.thepharmaletter.com/article/vectura-and-inspira-to-develop-potential-inhaled-covid-19-treatment", "pubDate": "2021-05-06 12:25:00"}, {"filename": "amryt-pharma-buying-chiasma-to-create-rare-diseases-powerhouse.json", "title": "Amryt Pharma buying Chiasma, to create rare diseases powerhouse", "description": "Amryt Pharma buying Chiasma, to create rare diseases powerhouse", "link": "https://www.thepharmaletter.com/article/amryt-pharma-buying-chiasma-to-create-rare-diseases-powerhouse", "pubDate": "2021-05-06 11:13:00"}, {"filename": "coronavirus-vaccine-approved-for-use-in-children.json", "title": "Coronavirus vaccine approved for use in children", "description": "Health Canada has approved a broader use of Comirnarty, the coronavirus vaccine from BioNTech and Pfizer, to include 12 to 15 year olds.", "link": "https://www.thepharmaletter.com/article/coronavirus-vaccine-approved-for-use-in-children", "pubDate": "2021-05-06 10:25:00"}, {"filename": "fda-accelerated-approval-to-keytruda-for-her2-positive-gastric-cancer.json", "title": "FDA accelerated approval to Keytruda for HER2-positive gastric cancer", "description": "FDA accelerated approval to Keytruda for HER2-positive gastric cancer", "link": "https://www.thepharmaletter.com/article/fda-accelerated-approval-to-keytruda-for-her2-positive-gastric-cancer", "pubDate": "2021-05-06 10:14:00"}, {"filename": "novo-nordisk-beats-expectations-in-quarterly-results.json", "title": "Novo Nordisk beats expectations in quarterly results", "description": "Danish diabetes giant Novo Nordisk exceeded analysts\u00e2\u0080\u0099 forecasts with its first quarter financial results, presented on Wednesday.", "link": "https://www.thepharmaletter.com/article/novo-nordisk-beats-expectations-in-quarterly-results", "pubDate": "2021-05-05 18:41:00"}, {"filename": "study-finds-tysabri-benefit-in-pregnant-women-with-ms.json", "title": "Study finds Tysabri benefit in pregnant women with MS", "description": "A study by Australia\u00e2\u0080\u0099s Monash University has highlighted the benefit for pregnant women with multiple sclerosis (MS) who continue to take a disease-modifying tr", "link": "https://www.thepharmaletter.com/article/study-finds-tysabri-benefit-in-pregnant-women-with-ms", "pubDate": "2021-05-05 16:24:00"}, {"filename": "merck-co-s-organon-spinoff-billed-as-good-news-for-all.json", "title": "Merck & Co\u00e2\u0080\u0099s Organon spinoff billed as good news for all", "description": "US pharma giant Merck & Co has detailed plans for the Organon spinoff.", "link": "https://www.thepharmaletter.com/article/merck-co-s-organon-spinoff-billed-as-good-news-for-all", "pubDate": "2021-05-05 15:12:00"}, {"filename": "oncimmune-and-genostics-company-part-ways-in-china.json", "title": "Oncimmune and Genostics Company part ways in China", "description": "Nottingham, UK-based immunodiagnostics specialist Oncimmune has taken back certain IP and distribution rights for its EarlyCDT technology.", "link": "https://www.thepharmaletter.com/article/oncimmune-and-genostics-company-part-ways-in-china", "pubDate": "2021-05-05 12:38:00"}, {"filename": "merck-s-perlmutter-joins-start-up-closes-148-million-series-a.json", "title": "Merck's Perlmutter joins start-up; closes $148 million Series A", "description": "Merck's Perlmutter joins start-up; closes $148 million Series A", "link": "https://www.thepharmaletter.com/article/merck-s-perlmutter-joins-start-up-closes-148-million-series-a", "pubDate": "2021-05-05 12:31:00"}, {"filename": "lung-cancer-approval-latest-good-news-story-for-tecentriq.json", "title": "Lung cancer approval latest good news story for Tecentriq", "description": "European authorities have granted marketing authorization for a new indication for Tecentriq (atezolizumab), the checkpoint blocker developed by Roche.", "link": "https://www.thepharmaletter.com/article/lung-cancer-approval-latest-good-news-story-for-tecentriq", "pubDate": "2021-05-05 11:16:00"}, {"filename": "cocrystal-pharma-soars-on-update-of-its-covid-19-antiviral-programs.json", "title": "Cocrystal Pharma soars on update of its COVID-19 antiviral programs", "description": "Cocrystal Pharma soars on update of its COVID-19 antiviral programs", "link": "https://www.thepharmaletter.com/article/cocrystal-pharma-soars-on-update-of-its-covid-19-antiviral-programs", "pubDate": "2021-05-05 10:57:00"}, {"filename": "exelixis-expands-its-biotherapeutics-portfolio.json", "title": "Exelixis expands its biotherapeutics portfolio", "description": "Exelixis expands its biotherapeutics portfolio", "link": "https://www.thepharmaletter.com/article/exelixis-expands-its-biotherapeutics-portfolio", "pubDate": "2021-05-05 10:17:00"}, {"filename": "nanolek-eyes-becoming-leading-vaccines-producer-in-russia.json", "title": "Nanolek eyes becoming leading vaccines producer in Russia", "description": "Nanolek eyes becoming leading vaccines producer in Russia", "link": "https://www.thepharmaletter.com/article/nanolek-eyes-becoming-leading-vaccines-producer-in-russia", "pubDate": "2021-05-05 10:16:00"}, {"filename": "takeda-launches-production-of-blood-cancer-drug-in-russia.json", "title": "Takeda launches production of blood cancer drug in Russia", "description": "Takeda launches production of blood cancer drug in Russia", "link": "https://www.thepharmaletter.com/article/takeda-launches-production-of-blood-cancer-drug-in-russia", "pubDate": "2021-05-05 10:15:00"}, {"filename": "positive-top-line-results-for-sobi-s-anakinra-in-covid-19-pneumonia.json", "title": "Positive top-line results for Sobi\u00e2\u0080\u0099s anakinra in COVID-19 pneumonia", "description": NaN, "link": "https://www.thepharmaletter.com/article/positive-top-line-results-for-sobi-s-anakinra-in-covid-19-pneumonia", "pubDate": "2021-05-04 17:47:00"}, {"filename": "avrobio-shares-suffer-on-forced-change-to-gene-therapy-development.json", "title": "Avrobio shares suffer on forced change to gene therapy development", "description": "Shares in US gene therapy company Avrobio closed 19% lower on Monday.", "link": "https://www.thepharmaletter.com/article/avrobio-shares-suffer-on-forced-change-to-gene-therapy-development", "pubDate": "2021-05-04 16:28:00"}, {"filename": "yarrow-biotechnology-in-licenses-proqr-s-aso-technology.json", "title": "Yarrow Biotechnology in-licenses ProQR\u00e2\u0080\u0099s ASO technology", "description": "Yarrow Biotechnology in-licenses ProQR\u00e2\u0080\u0099s ASO technology", "link": "https://www.thepharmaletter.com/article/yarrow-biotechnology-in-licenses-proqr-s-aso-technology", "pubDate": "2021-05-04 15:00:00"}, {"filename": "pfizer-adds-3-5-billion-in-first-quarter-vaccine-sales.json", "title": "Pfizer adds $3.5 billion in first-quarter vaccine sales", "description": "Sales of Comirnarty, Pfizer\u00e2\u0080\u0099s BioNTech-partnered coronavirus vaccine, led the firm to a better-than-expected first quarter, with revenues up 45% at $14.6 billio", "link": "https://www.thepharmaletter.com/article/pfizer-adds-3-5-billion-in-first-quarter-vaccine-sales", "pubDate": "2021-05-04 14:30:00"}, {"filename": "novobiome-launched-to-revolutionize-treatment-of-liver-diseases-by-targeting-the-microbiome-gut-liver-axis.json", "title": "NovoBiome launched to \u00e2\u0080\u0098revolutionize treatment of liver diseases by targeting the microbiome-gut-liver axis\u00e2\u0080\u0099", "description": "The launch of French drug discovery company NovoBiome has been announced.", "link": "https://www.thepharmaletter.com/article/novobiome-launched-to-revolutionize-treatment-of-liver-diseases-by-targeting-the-microbiome-gut-liver-axis", "pubDate": "2021-05-04 14:18:00"}, {"filename": "launch-of-moonlake-immunotherapeutics-with-in-license-of-merck-s-il-17-nanobody.json", "title": "Launch of MoonLake Immunotherapeutics with in-license of Merck's IL-17 nanobody", "description": "Launch of MoonLake Immunotherapeutics with in-license of Merck's IL-17 nanobody", "link": "https://www.thepharmaletter.com/article/launch-of-moonlake-immunotherapeutics-with-in-license-of-merck-s-il-17-nanobody", "pubDate": "2021-05-04 14:03:00"}, {"filename": "sarepta-leaps-on-positive-srp-5051-results-in-patients-with-dmd.json", "title": "Sarepta leaps on mainly positive SRP-5051 results in patients with DMD", "description": "Sarepta leaps on mainly positive SRP-5051 results in patients with DMD", "link": "https://www.thepharmaletter.com/article/sarepta-leaps-on-positive-srp-5051-results-in-patients-with-dmd", "pubDate": "2021-05-04 12:39:00"}, {"filename": "ec-approval-for-advicenne-s-adv7103-sibnayal.json", "title": "EC approval for Advicenne\u00e2\u0080\u0099s ADV7103/Sibnayal", "description": "EC approval for Advicenne\u00e2\u0080\u0099s ADV7103/Sibnayal", "link": "https://www.thepharmaletter.com/article/ec-approval-for-advicenne-s-adv7103-sibnayal", "pubDate": "2021-05-04 11:44:00"}, {"filename": "moderna-offers-500-million-doses-for-developing-countries-but-not-this-year.json", "title": "Moderna offers 500 million doses for developing countries, but not this year", "description": "As India battles a surge in coronavirus cases, with over 20 million infections nationwide and hospitals running low on oxygen, there is a pressing need to bolst", "link": "https://www.thepharmaletter.com/article/moderna-offers-500-million-doses-for-developing-countries-but-not-this-year", "pubDate": "2021-05-04 11:21:00"}, {"filename": "chiesi-gains-new-us-appro-for-ferriprox.json", "title": "Chiesi gains new US appro for Ferriprox", "description": "Chiesi gains new US appro for Ferriprox", "link": "https://www.thepharmaletter.com/article/chiesi-gains-new-us-appro-for-ferriprox", "pubDate": "2021-05-04 10:14:00"}, {"filename": "roivant-merging-with-montes-archimedes-to-go-public-in-7-3-billion-spav-deal.json", "title": "Roivant merging with Montes Archimedes to go public in $7.3 billion SPAC deal", "description": "Roivant merging with Montes Archimedes to go public in $7.3 billion SPAC deal", "link": "https://www.thepharmaletter.com/article/roivant-merging-with-montes-archimedes-to-go-public-in-7-3-billion-spav-deal", "pubDate": "2021-05-04 10:13:00"}, {"filename": "progress-on-proposed-biosimilars-of-eye-drugs-eylea-and-lucentis.json", "title": "Progress on proposed biosimilars of eye drugs Eylea and Lucentis", "description": "Progress on proposed biosimilars of eye drugs Eylea and Lucentis", "link": "https://www.thepharmaletter.com/article/progress-on-proposed-biosimilars-of-eye-drugs-eylea-and-lucentis", "pubDate": "2021-05-04 10:12:00"}, {"filename": "glenmark-launches-ryaltris-az-at-an-affordable-price-in-india.json", "title": "Glenmark launches Ryaltris-AZ at an affordable price in India", "description": "Glenmark launches Ryaltris-AZ at an affordable price in India", "link": "https://www.thepharmaletter.com/article/glenmark-launches-ryaltris-az-at-an-affordable-price-in-india", "pubDate": "2021-05-04 10:11:00"}, {"filename": "aiding-india-s-vaccine-efforts-diplomatically.json", "title": "Aiding India's vaccine efforts - diplomatically", "description": "Aiding India's vaccine efforts - diplomatically", "link": "https://www.thepharmaletter.com/article/aiding-india-s-vaccine-efforts-diplomatically", "pubDate": "2021-05-04 10:10:00"}, {"filename": "another-coronavirus-vaccine-trial-in-children-to-commence.json", "title": "Another coronavirus vaccine trial in children to begin", "description": "Maryland, USA-based vaccine specialist Novavax is to commence Phase III trials of its coronavirus vaccine candidate in children aged 12 to 17.", "link": "https://www.thepharmaletter.com/article/another-coronavirus-vaccine-trial-in-children-to-commence", "pubDate": "2021-05-04 09:48:00"}, {"filename": "positive-phase-iii-results-for-novartis-beovu-in-dme.json", "title": "Positive Phase III results for Novartis\u00e2\u0080\u0099 Beovu IN DME", "description": "Positive Phase III results for Novartis\u00e2\u0080\u0099 Beovu IN DME", "link": "https://www.thepharmaletter.com/article/positive-phase-iii-results-for-novartis-beovu-in-dme", "pubDate": "2021-05-02 14:02:00"}, {"filename": "look-back-at-pharma-news-in-the-week-to-april-30-2021.json", "title": "Look back at pharma news in the week to April 30, 2021", "description": "Look back at pharma news in the week to April 30, 2021", "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-april-30-2021", "pubDate": "2021-05-02 11:07:00"}, {"filename": "mma-filed-for-legend-biotech-and-janssen-s-for-cilta-cell-in-europe.json", "title": "MAA filed for Legend Biotech and Janssen\u00e2\u0080\u0099s for cilta-cell in Europe", "description": "MMA filed for Legend Biotech and Janssen\u00e2\u0080\u0099s for cilta-cell in Europe", "link": "https://www.thepharmaletter.com/article/mma-filed-for-legend-biotech-and-janssen-s-for-cilta-cell-in-europe", "pubDate": "2021-05-01 15:25:00"}, {"filename": "fda-approves-treatment-for-chronic-kidney-disease.json", "title": "FDA approves treatment for chronic kidney disease", "description": "FDA approves treatment for chronic kidney disease", "link": "https://www.thepharmaletter.com/article/fda-approves-treatment-for-chronic-kidney-disease", "pubDate": "2021-05-01 14:47:00"}, {"filename": "cancer-drug-lorviqua-granted-innovation-passport-from-uk-regulator.json", "title": "Cancer drug Lorviqua granted \u00e2\u0080\u0098Innovation Passport\u00e2\u0080\u0099 from UK regulator", "description": "Cancer drug Lorviqua granted \u00e2\u0080\u0098Innovation Passport\u00e2\u0080\u0099 from UK regulator", "link": "https://www.thepharmaletter.com/article/cancer-drug-lorviqua-granted-innovation-passport-from-uk-regulator", "pubDate": "2021-05-01 14:01:00"}]